EP Patent

EP4684778A1 — Pharmaceutical composition against sars-cov-2 and preparation method therefor

Assigned to Guangdong Raynovent Biotech Co Ltd · Expires 2026-01-28 · 0y expired

What this patent protects

Provided is a pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and an auxiliary material. The auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant. The pharmaceutical …

USPTO Abstract

Provided is a pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and an auxiliary material. The auxiliary material comprises one or more of a filler, a binder, a glidant, a disintegrant and a lubricant. The pharmaceutical composition has the feasibility of preparation process, excellent properties of preparations, good stability and good dissolution, and meets the pharmaceutical standards.

Drugs covered by this patent

Patent Metadata

Patent number
EP4684778A1
Jurisdiction
EP
Classification
—
Expires
2026-01-28
Drug substance claim
No
Drug product claim
No
Assignee
Guangdong Raynovent Biotech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.